Data from a large study of national health care claims databases revealed that new-onset psychosis occurred in about one in 660 patients aged 13 to 25 years receiving prescription stimulants; however, the risk for psychosis was greater among those prescribed amphetamine than those prescribed methylphenidate.
“There is not a lot of research comparing the safety profiles of amphetamines and methylphenidate, despite increasing use of these medications," Lauren V. Moran, MD, from the division of pharmacoepidemiology and pharmacoeconomics at Brigham and Women’s Hospital, and the division of psychotic disorders at McLean Hospital, said in a press release.
This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.